|View printer-friendly version|
- Processa is led by a management team with a proven track record in drug development and drug delivery
“We are excited to form this new relationship with Processa. Dr.
“The Processa team and I are excited about accessing the HyStem technology platform as a way to address the numerous challenges that exist within drug delivery. This technology has the potential to be beneficial for many drugs. We are keen to make progress on the development of the HyStem platform for drug delivery,” said Dr.
HyStem® is BioTime’s cell and drug delivery platform. HyStem® technology includes a family of unique, biocompatible hydrogels designed to effectively deliver cells or bioactive compositions for therapeutic benefit. HyStem® was designed to enable the effective transfer, engraftment and metabolic support for cells and is the basis of BioTime’s Renevia® program. The flexible chemistry of the HyStem® also allows for hydrogel optimization in the delivery of drugs and therapeutics.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn,
To receive ongoing
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for